カテゴリー： 世界, 医療/バイオ, GlobalInfoResearch

世界の癌に対するモノクローナル抗体市場2023年：企業・地域・タイプ・用途別分析

【英語タイトル】Global Monoclonal Antibodies for Cancers Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

GlobalInfoResearchが出版した調査資料（GIR23SM7938）・商品コード：GIR23SM7938
・発行会社（調査会社）：GlobalInfoResearch
・発行日：2023年9月
・ページ数：107
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（注文後2-3日）
・調査対象地域：グローバル
・産業分野：医薬品＆ヘルスケア
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

GlobalInfoResearchの最新の調査によると、世界の癌に対するモノクローナル抗体の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の癌に対するモノクローナル抗体市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、タイプ別、用途別に記載されています。

市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。

本レポートの主な目的は次のとおりです。
- 世界および主要国の市場機会の規模を決定するため
- 癌に対するモノクローナル抗体の成長可能性を評価するため
- 各製品および最終用途市場の将来の成長を予測するため
- 市場に影響を与える競争要因を評価するため

癌に対するモノクローナル抗体市場はタイプと用途によって区分されます。2018年～2029年において、量と金額の観点からタイプ別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

タイプ別セグメント
・リツキシマブ、トラスツズマブ、ベバシズマブ、その他

用途別セグメント
・リンパ腫、非小細胞肺がん（NSCLC）、乳がん、子宮頸がん、その他

主要な市場プレーヤー
・AbbVie、Merck、Roche、Bristol Myers Squibb、Daiichi Sankyo、Johnson & Johnson、Biogen、Novartis、Takeda Pharmaceuticals、Astellas Pharma、Qilu Pharmaceutical、Luye Pharma、Hengrui Pharmaceuticals、Innovent

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、癌に対するモノクローナル抗体製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な癌に対するモノクローナル抗体メーカーの企業概要、2019年～2022年までの癌に対するモノクローナル抗体の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な癌に対するモノクローナル抗体メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別癌に対するモノクローナル抗体の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの癌に対するモノクローナル抗体のタイプ別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での癌に対するモノクローナル抗体市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および癌に対するモノクローナル抗体の産業チェーンを掲載しています。
・第14、15章では、癌に対するモノクローナル抗体の販売チャネル、販売業者、顧客、調査結果について説明します。

・市場概要
– 癌に対するモノクローナル抗体の概要
– タイプ別分析（2018年vs2022年vs2029年）：リツキシマブ、トラスツズマブ、ベバシズマブ、その他
– 用途別分析（2018年vs2022年vs2029年）：リンパ腫、非小細胞肺がん（NSCLC）、乳がん、子宮頸がん、その他
– 世界の癌に対するモノクローナル抗体市場規模・予測
– 世界の癌に対するモノクローナル抗体生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– AbbVie、Merck、Roche、Bristol Myers Squibb、Daiichi Sankyo、Johnson & Johnson、Biogen、Novartis、Takeda Pharmaceuticals、Astellas Pharma、Qilu Pharmaceutical、Luye Pharma、Hengrui Pharmaceuticals、Innovent
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・タイプ別分析2018年-2029年：リツキシマブ、トラスツズマブ、ベバシズマブ、その他
・用途別分析2018年-2029年：リンパ腫、非小細胞肺がん（NSCLC）、乳がん、子宮頸がん、その他
・癌に対するモノクローナル抗体の北米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・癌に対するモノクローナル抗体のヨーロッパ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・癌に対するモノクローナル抗体のアジア市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・癌に対するモノクローナル抗体の南米市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・癌に対するモノクローナル抗体の中東・アフリカ市場
– タイプ別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

1 Market Overview
1.1 Product Overview and Scope of Monoclonal Antibodies for Cancers
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Monoclonal Antibodies for Cancers Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Rituximab
1.3.3 Trastuzumab
1.3.4 Bevacizumab
1.3.5 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Monoclonal Antibodies for Cancers Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Lymphoma
1.4.3 Non-small Cell Lung Cancer (NSCLC)
1.4.4 Breast Cancer
1.4.5 Cervical Cancer
1.4.6 Others
1.5 Global Monoclonal Antibodies for Cancers Market Size & Forecast
1.5.1 Global Monoclonal Antibodies for Cancers Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Monoclonal Antibodies for Cancers Sales Quantity (2018-2029)
1.5.3 Global Monoclonal Antibodies for Cancers Average Price (2018-2029)
2 Manufacturers Profiles
2.1 AbbVie
2.1.1 AbbVie Details
2.1.2 AbbVie Major Business
2.1.3 AbbVie Monoclonal Antibodies for Cancers Product and Services
2.1.4 AbbVie Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AbbVie Recent Developments/Updates
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck Monoclonal Antibodies for Cancers Product and Services
2.2.4 Merck Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Merck Recent Developments/Updates
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Monoclonal Antibodies for Cancers Product and Services
2.3.4 Roche Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Roche Recent Developments/Updates
2.4 Bristol Myers Squibb
2.4.1 Bristol Myers Squibb Details
2.4.2 Bristol Myers Squibb Major Business
2.4.3 Bristol Myers Squibb Monoclonal Antibodies for Cancers Product and Services
2.4.4 Bristol Myers Squibb Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Bristol Myers Squibb Recent Developments/Updates
2.5 Daiichi Sankyo
2.5.1 Daiichi Sankyo Details
2.5.2 Daiichi Sankyo Major Business
2.5.3 Daiichi Sankyo Monoclonal Antibodies for Cancers Product and Services
2.5.4 Daiichi Sankyo Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Daiichi Sankyo Recent Developments/Updates
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson Monoclonal Antibodies for Cancers Product and Services
2.6.4 Johnson & Johnson Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Johnson & Johnson Recent Developments/Updates
2.7 Biogen
2.7.1 Biogen Details
2.7.2 Biogen Major Business
2.7.3 Biogen Monoclonal Antibodies for Cancers Product and Services
2.7.4 Biogen Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Biogen Recent Developments/Updates
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Monoclonal Antibodies for Cancers Product and Services
2.8.4 Novartis Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Novartis Recent Developments/Updates
2.9 Takeda Pharmaceuticals
2.9.1 Takeda Pharmaceuticals Details
2.9.2 Takeda Pharmaceuticals Major Business
2.9.3 Takeda Pharmaceuticals Monoclonal Antibodies for Cancers Product and Services
2.9.4 Takeda Pharmaceuticals Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Takeda Pharmaceuticals Recent Developments/Updates
2.10 Astellas Pharma
2.10.1 Astellas Pharma Details
2.10.2 Astellas Pharma Major Business
2.10.3 Astellas Pharma Monoclonal Antibodies for Cancers Product and Services
2.10.4 Astellas Pharma Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Astellas Pharma Recent Developments/Updates
2.11 Qilu Pharmaceutical
2.11.1 Qilu Pharmaceutical Details
2.11.2 Qilu Pharmaceutical Major Business
2.11.3 Qilu Pharmaceutical Monoclonal Antibodies for Cancers Product and Services
2.11.4 Qilu Pharmaceutical Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 Qilu Pharmaceutical Recent Developments/Updates
2.12 Luye Pharma
2.12.1 Luye Pharma Details
2.12.2 Luye Pharma Major Business
2.12.3 Luye Pharma Monoclonal Antibodies for Cancers Product and Services
2.12.4 Luye Pharma Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Luye Pharma Recent Developments/Updates
2.13 Hengrui Pharmaceuticals
2.13.1 Hengrui Pharmaceuticals Details
2.13.2 Hengrui Pharmaceuticals Major Business
2.13.3 Hengrui Pharmaceuticals Monoclonal Antibodies for Cancers Product and Services
2.13.4 Hengrui Pharmaceuticals Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.13.5 Hengrui Pharmaceuticals Recent Developments/Updates
2.14 Innovent
2.14.1 Innovent Details
2.14.2 Innovent Major Business
2.14.3 Innovent Monoclonal Antibodies for Cancers Product and Services
2.14.4 Innovent Monoclonal Antibodies for Cancers Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.14.5 Innovent Recent Developments/Updates
3 Competitive Environment: Monoclonal Antibodies for Cancers by Manufacturer
3.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Manufacturer (2018-2023)
3.2 Global Monoclonal Antibodies for Cancers Revenue by Manufacturer (2018-2023)
3.3 Global Monoclonal Antibodies for Cancers Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Monoclonal Antibodies for Cancers by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Monoclonal Antibodies for Cancers Manufacturer Market Share in 2022
3.4.2 Top 6 Monoclonal Antibodies for Cancers Manufacturer Market Share in 2022
3.5 Monoclonal Antibodies for Cancers Market: Overall Company Footprint Analysis
3.5.1 Monoclonal Antibodies for Cancers Market: Region Footprint
3.5.2 Monoclonal Antibodies for Cancers Market: Company Product Type Footprint
3.5.3 Monoclonal Antibodies for Cancers Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Monoclonal Antibodies for Cancers Market Size by Region
4.1.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Region (2018-2029)
4.1.2 Global Monoclonal Antibodies for Cancers Consumption Value by Region (2018-2029)
4.1.3 Global Monoclonal Antibodies for Cancers Average Price by Region (2018-2029)
4.2 North America Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
4.3 Europe Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
4.4 Asia-Pacific Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
4.5 South America Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
4.6 Middle East and Africa Monoclonal Antibodies for Cancers Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
5.2 Global Monoclonal Antibodies for Cancers Consumption Value by Type (2018-2029)
5.3 Global Monoclonal Antibodies for Cancers Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
6.2 Global Monoclonal Antibodies for Cancers Consumption Value by Application (2018-2029)
6.3 Global Monoclonal Antibodies for Cancers Average Price by Application (2018-2029)
7 North America
7.1 North America Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
7.2 North America Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
7.3 North America Monoclonal Antibodies for Cancers Market Size by Country
7.3.1 North America Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
7.3.2 North America Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
8.2 Europe Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
8.3 Europe Monoclonal Antibodies for Cancers Market Size by Country
8.3.1 Europe Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
8.3.2 Europe Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Monoclonal Antibodies for Cancers Market Size by Region
9.3.1 Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Monoclonal Antibodies for Cancers Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
10.2 South America Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
10.3 South America Monoclonal Antibodies for Cancers Market Size by Country
10.3.1 South America Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
10.3.2 South America Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Monoclonal Antibodies for Cancers Market Size by Country
11.3.1 Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Monoclonal Antibodies for Cancers Market Drivers
12.2 Monoclonal Antibodies for Cancers Market Restraints
12.3 Monoclonal Antibodies for Cancers Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Monoclonal Antibodies for Cancers and Key Manufacturers
13.2 Manufacturing Costs Percentage of Monoclonal Antibodies for Cancers
13.3 Monoclonal Antibodies for Cancers Production Process
13.4 Monoclonal Antibodies for Cancers Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Monoclonal Antibodies for Cancers Typical Distributors
14.3 Monoclonal Antibodies for Cancers Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

List of Tables
Table 1. Global Monoclonal Antibodies for Cancers Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Monoclonal Antibodies for Cancers Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. AbbVie Basic Information, Manufacturing Base and Competitors
Table 4. AbbVie Major Business
Table 5. AbbVie Monoclonal Antibodies for Cancers Product and Services
Table 6. AbbVie Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. AbbVie Recent Developments/Updates
Table 8. Merck Basic Information, Manufacturing Base and Competitors
Table 9. Merck Major Business
Table 10. Merck Monoclonal Antibodies for Cancers Product and Services
Table 11. Merck Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Merck Recent Developments/Updates
Table 13. Roche Basic Information, Manufacturing Base and Competitors
Table 14. Roche Major Business
Table 15. Roche Monoclonal Antibodies for Cancers Product and Services
Table 16. Roche Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Roche Recent Developments/Updates
Table 18. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 19. Bristol Myers Squibb Major Business
Table 20. Bristol Myers Squibb Monoclonal Antibodies for Cancers Product and Services
Table 21. Bristol Myers Squibb Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Bristol Myers Squibb Recent Developments/Updates
Table 23. Daiichi Sankyo Basic Information, Manufacturing Base and Competitors
Table 24. Daiichi Sankyo Major Business
Table 25. Daiichi Sankyo Monoclonal Antibodies for Cancers Product and Services
Table 26. Daiichi Sankyo Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Daiichi Sankyo Recent Developments/Updates
Table 28. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 29. Johnson & Johnson Major Business
Table 30. Johnson & Johnson Monoclonal Antibodies for Cancers Product and Services
Table 31. Johnson & Johnson Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Johnson & Johnson Recent Developments/Updates
Table 33. Biogen Basic Information, Manufacturing Base and Competitors
Table 34. Biogen Major Business
Table 35. Biogen Monoclonal Antibodies for Cancers Product and Services
Table 36. Biogen Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Biogen Recent Developments/Updates
Table 38. Novartis Basic Information, Manufacturing Base and Competitors
Table 39. Novartis Major Business
Table 40. Novartis Monoclonal Antibodies for Cancers Product and Services
Table 41. Novartis Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Novartis Recent Developments/Updates
Table 43. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 44. Takeda Pharmaceuticals Major Business
Table 45. Takeda Pharmaceuticals Monoclonal Antibodies for Cancers Product and Services
Table 46. Takeda Pharmaceuticals Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Takeda Pharmaceuticals Recent Developments/Updates
Table 48. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 49. Astellas Pharma Major Business
Table 50. Astellas Pharma Monoclonal Antibodies for Cancers Product and Services
Table 51. Astellas Pharma Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Astellas Pharma Recent Developments/Updates
Table 53. Qilu Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 54. Qilu Pharmaceutical Major Business
Table 55. Qilu Pharmaceutical Monoclonal Antibodies for Cancers Product and Services
Table 56. Qilu Pharmaceutical Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 57. Qilu Pharmaceutical Recent Developments/Updates
Table 58. Luye Pharma Basic Information, Manufacturing Base and Competitors
Table 59. Luye Pharma Major Business
Table 60. Luye Pharma Monoclonal Antibodies for Cancers Product and Services
Table 61. Luye Pharma Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 62. Luye Pharma Recent Developments/Updates
Table 63. Hengrui Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 64. Hengrui Pharmaceuticals Major Business
Table 65. Hengrui Pharmaceuticals Monoclonal Antibodies for Cancers Product and Services
Table 66. Hengrui Pharmaceuticals Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 67. Hengrui Pharmaceuticals Recent Developments/Updates
Table 68. Innovent Basic Information, Manufacturing Base and Competitors
Table 69. Innovent Major Business
Table 70. Innovent Monoclonal Antibodies for Cancers Product and Services
Table 71. Innovent Monoclonal Antibodies for Cancers Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 72. Innovent Recent Developments/Updates
Table 73. Global Monoclonal Antibodies for Cancers Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 74. Global Monoclonal Antibodies for Cancers Revenue by Manufacturer (2018-2023) & (USD Million)
Table 75. Global Monoclonal Antibodies for Cancers Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 76. Market Position of Manufacturers in Monoclonal Antibodies for Cancers, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 77. Head Office and Monoclonal Antibodies for Cancers Production Site of Key Manufacturer
Table 78. Monoclonal Antibodies for Cancers Market: Company Product Type Footprint
Table 79. Monoclonal Antibodies for Cancers Market: Company Product Application Footprint
Table 80. Monoclonal Antibodies for Cancers New Market Entrants and Barriers to Market Entry
Table 81. Monoclonal Antibodies for Cancers Mergers, Acquisition, Agreements, and Collaborations
Table 82. Global Monoclonal Antibodies for Cancers Sales Quantity by Region (2018-2023) & (K Units)
Table 83. Global Monoclonal Antibodies for Cancers Sales Quantity by Region (2024-2029) & (K Units)
Table 84. Global Monoclonal Antibodies for Cancers Consumption Value by Region (2018-2023) & (USD Million)
Table 85. Global Monoclonal Antibodies for Cancers Consumption Value by Region (2024-2029) & (USD Million)
Table 86. Global Monoclonal Antibodies for Cancers Average Price by Region (2018-2023) & (US$/Unit)
Table 87. Global Monoclonal Antibodies for Cancers Average Price by Region (2024-2029) & (US$/Unit)
Table 88. Global Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Global Monoclonal Antibodies for Cancers Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Global Monoclonal Antibodies for Cancers Consumption Value by Type (2018-2023) & (USD Million)
Table 91. Global Monoclonal Antibodies for Cancers Consumption Value by Type (2024-2029) & (USD Million)
Table 92. Global Monoclonal Antibodies for Cancers Average Price by Type (2018-2023) & (US$/Unit)
Table 93. Global Monoclonal Antibodies for Cancers Average Price by Type (2024-2029) & (US$/Unit)
Table 94. Global Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2023) & (K Units)
Table 95. Global Monoclonal Antibodies for Cancers Sales Quantity by Application (2024-2029) & (K Units)
Table 96. Global Monoclonal Antibodies for Cancers Consumption Value by Application (2018-2023) & (USD Million)
Table 97. Global Monoclonal Antibodies for Cancers Consumption Value by Application (2024-2029) & (USD Million)
Table 98. Global Monoclonal Antibodies for Cancers Average Price by Application (2018-2023) & (US$/Unit)
Table 99. Global Monoclonal Antibodies for Cancers Average Price by Application (2024-2029) & (US$/Unit)
Table 100. North America Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2023) & (K Units)
Table 101. North America Monoclonal Antibodies for Cancers Sales Quantity by Type (2024-2029) & (K Units)
Table 102. North America Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2023) & (K Units)
Table 103. North America Monoclonal Antibodies for Cancers Sales Quantity by Application (2024-2029) & (K Units)
Table 104. North America Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2023) & (K Units)
Table 105. North America Monoclonal Antibodies for Cancers Sales Quantity by Country (2024-2029) & (K Units)
Table 106. North America Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2023) & (USD Million)
Table 107. North America Monoclonal Antibodies for Cancers Consumption Value by Country (2024-2029) & (USD Million)
Table 108. Europe Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2023) & (K Units)
Table 109. Europe Monoclonal Antibodies for Cancers Sales Quantity by Type (2024-2029) & (K Units)
Table 110. Europe Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2023) & (K Units)
Table 111. Europe Monoclonal Antibodies for Cancers Sales Quantity by Application (2024-2029) & (K Units)
Table 112. Europe Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2023) & (K Units)
Table 113. Europe Monoclonal Antibodies for Cancers Sales Quantity by Country (2024-2029) & (K Units)
Table 114. Europe Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2023) & (USD Million)
Table 115. Europe Monoclonal Antibodies for Cancers Consumption Value by Country (2024-2029) & (USD Million)
Table 116. Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2023) & (K Units)
Table 117. Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Type (2024-2029) & (K Units)
Table 118. Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2023) & (K Units)
Table 119. Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Application (2024-2029) & (K Units)
Table 120. Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Region (2018-2023) & (K Units)
Table 121. Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity by Region (2024-2029) & (K Units)
Table 122. Asia-Pacific Monoclonal Antibodies for Cancers Consumption Value by Region (2018-2023) & (USD Million)
Table 123. Asia-Pacific Monoclonal Antibodies for Cancers Consumption Value by Region (2024-2029) & (USD Million)
Table 124. South America Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2023) & (K Units)
Table 125. South America Monoclonal Antibodies for Cancers Sales Quantity by Type (2024-2029) & (K Units)
Table 126. South America Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2023) & (K Units)
Table 127. South America Monoclonal Antibodies for Cancers Sales Quantity by Application (2024-2029) & (K Units)
Table 128. South America Monoclonal Antibodies for Cancers Sales Quantity by Country (2018-2023) & (K Units)
Table 129. South America Monoclonal Antibodies for Cancers Sales Quantity by Country (2024-2029) & (K Units)
Table 130. South America Monoclonal Antibodies for Cancers Consumption Value by Country (2018-2023) & (USD Million)
Table 131. South America Monoclonal Antibodies for Cancers Consumption Value by Country (2024-2029) & (USD Million)
Table 132. Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Type (2018-2023) & (K Units)
Table 133. Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Type (2024-2029) & (K Units)
Table 134. Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Application (2018-2023) & (K Units)
Table 135. Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Application (2024-2029) & (K Units)
Table 136. Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Region (2018-2023) & (K Units)
Table 137. Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity by Region (2024-2029) & (K Units)
Table 138. Middle East & Africa Monoclonal Antibodies for Cancers Consumption Value by Region (2018-2023) & (USD Million)
Table 139. Middle East & Africa Monoclonal Antibodies for Cancers Consumption Value by Region (2024-2029) & (USD Million)
Table 140. Monoclonal Antibodies for Cancers Raw Material
Table 141. Key Manufacturers of Monoclonal Antibodies for Cancers Raw Materials
Table 142. Monoclonal Antibodies for Cancers Typical Distributors
Table 143. Monoclonal Antibodies for Cancers Typical Customers
List of Figures
Figure 1. Monoclonal Antibodies for Cancers Picture
Figure 2. Global Monoclonal Antibodies for Cancers Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Monoclonal Antibodies for Cancers Consumption Value Market Share by Type in 2022
Figure 4. Rituximab Examples
Figure 5. Trastuzumab Examples
Figure 6. Bevacizumab Examples
Figure 7. Others Examples
Figure 8. Global Monoclonal Antibodies for Cancers Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Monoclonal Antibodies for Cancers Consumption Value Market Share by Application in 2022
Figure 10. Lymphoma Examples
Figure 11. Non-small Cell Lung Cancer (NSCLC) Examples
Figure 12. Breast Cancer Examples
Figure 13. Cervical Cancer Examples
Figure 14. Others Examples
Figure 15. Global Monoclonal Antibodies for Cancers Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 16. Global Monoclonal Antibodies for Cancers Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 17. Global Monoclonal Antibodies for Cancers Sales Quantity (2018-2029) & (K Units)
Figure 18. Global Monoclonal Antibodies for Cancers Average Price (2018-2029) & (US$/Unit)
Figure 19. Global Monoclonal Antibodies for Cancers Sales Quantity Market Share by Manufacturer in 2022
Figure 20. Global Monoclonal Antibodies for Cancers Consumption Value Market Share by Manufacturer in 2022
Figure 21. Producer Shipments of Monoclonal Antibodies for Cancers by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 22. Top 3 Monoclonal Antibodies for Cancers Manufacturer (Consumption Value) Market Share in 2022
Figure 23. Top 6 Monoclonal Antibodies for Cancers Manufacturer (Consumption Value) Market Share in 2022
Figure 24. Global Monoclonal Antibodies for Cancers Sales Quantity Market Share by Region (2018-2029)
Figure 25. Global Monoclonal Antibodies for Cancers Consumption Value Market Share by Region (2018-2029)
Figure 26. North America Monoclonal Antibodies for Cancers Consumption Value (2018-2029) & (USD Million)
Figure 27. Europe Monoclonal Antibodies for Cancers Consumption Value (2018-2029) & (USD Million)
Figure 28. Asia-Pacific Monoclonal Antibodies for Cancers Consumption Value (2018-2029) & (USD Million)
Figure 29. South America Monoclonal Antibodies for Cancers Consumption Value (2018-2029) & (USD Million)
Figure 30. Middle East & Africa Monoclonal Antibodies for Cancers Consumption Value (2018-2029) & (USD Million)
Figure 31. Global Monoclonal Antibodies for Cancers Sales Quantity Market Share by Type (2018-2029)
Figure 32. Global Monoclonal Antibodies for Cancers Consumption Value Market Share by Type (2018-2029)
Figure 33. Global Monoclonal Antibodies for Cancers Average Price by Type (2018-2029) & (US$/Unit)
Figure 34. Global Monoclonal Antibodies for Cancers Sales Quantity Market Share by Application (2018-2029)
Figure 35. Global Monoclonal Antibodies for Cancers Consumption Value Market Share by Application (2018-2029)
Figure 36. Global Monoclonal Antibodies for Cancers Average Price by Application (2018-2029) & (US$/Unit)
Figure 37. North America Monoclonal Antibodies for Cancers Sales Quantity Market Share by Type (2018-2029)
Figure 38. North America Monoclonal Antibodies for Cancers Sales Quantity Market Share by Application (2018-2029)
Figure 39. North America Monoclonal Antibodies for Cancers Sales Quantity Market Share by Country (2018-2029)
Figure 40. North America Monoclonal Antibodies for Cancers Consumption Value Market Share by Country (2018-2029)
Figure 41. United States Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 42. Canada Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Mexico Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Europe Monoclonal Antibodies for Cancers Sales Quantity Market Share by Type (2018-2029)
Figure 45. Europe Monoclonal Antibodies for Cancers Sales Quantity Market Share by Application (2018-2029)
Figure 46. Europe Monoclonal Antibodies for Cancers Sales Quantity Market Share by Country (2018-2029)
Figure 47. Europe Monoclonal Antibodies for Cancers Consumption Value Market Share by Country (2018-2029)
Figure 48. Germany Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. France Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. United Kingdom Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. Russia Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Italy Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity Market Share by Type (2018-2029)
Figure 54. Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity Market Share by Application (2018-2029)
Figure 55. Asia-Pacific Monoclonal Antibodies for Cancers Sales Quantity Market Share by Region (2018-2029)
Figure 56. Asia-Pacific Monoclonal Antibodies for Cancers Consumption Value Market Share by Region (2018-2029)
Figure 57. China Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Japan Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Korea Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. India Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. Southeast Asia Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Australia Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. South America Monoclonal Antibodies for Cancers Sales Quantity Market Share by Type (2018-2029)
Figure 64. South America Monoclonal Antibodies for Cancers Sales Quantity Market Share by Application (2018-2029)
Figure 65. South America Monoclonal Antibodies for Cancers Sales Quantity Market Share by Country (2018-2029)
Figure 66. South America Monoclonal Antibodies for Cancers Consumption Value Market Share by Country (2018-2029)
Figure 67. Brazil Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 68. Argentina Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity Market Share by Type (2018-2029)
Figure 70. Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity Market Share by Application (2018-2029)
Figure 71. Middle East & Africa Monoclonal Antibodies for Cancers Sales Quantity Market Share by Region (2018-2029)
Figure 72. Middle East & Africa Monoclonal Antibodies for Cancers Consumption Value Market Share by Region (2018-2029)
Figure 73. Turkey Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Egypt Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Saudi Arabia Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. South Africa Monoclonal Antibodies for Cancers Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. Monoclonal Antibodies for Cancers Market Drivers
Figure 78. Monoclonal Antibodies for Cancers Market Restraints
Figure 79. Monoclonal Antibodies for Cancers Market Trends
Figure 80. Porters Five Forces Analysis
Figure 81. Manufacturing Cost Structure Analysis of Monoclonal Antibodies for Cancers in 2022
Figure 82. Manufacturing Process Analysis of Monoclonal Antibodies for Cancers
Figure 83. Monoclonal Antibodies for Cancers Industrial Chain
Figure 84. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 85. Direct Channel Pros & Cons
Figure 86. Indirect Channel Pros & Cons
Figure 87. Methodology
Figure 88. Research Process and Data Source


★調査レポート[世界の癌に対するモノクローナル抗体市場2023年：企業・地域・タイプ・用途別分析] (コード：GIR23SM7938)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の癌に対するモノクローナル抗体市場2023年：企業・地域・タイプ・用途別分析]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のヘパラン硫酸抗体市場2023年：企業・地域・タイプ・用途別分析
  • 世界のレテルモビル注射市場2023年：企業・地域・タイプ・用途別分析
  • 世界の単回使用胃カメラ市場2023年：企業・地域・タイプ・用途別分析
  • 世界のボスチニブ一水和物錠市場2023年：企業・地域・タイプ・用途別分析
  • 世界のピーナッツプロテインパッチ市場2023年：企業・地域・タイプ・用途別分析
  • 世界のスプレー凍結療法装置市場2023年：企業・地域・タイプ・用途別分析
  • 世界のC5補体阻害剤市場2023年：企業・地域・タイプ・用途別分析
  • 世界のイリジウム-192線源市場2023年：企業・地域・タイプ・用途別分析
  • 世界のミオグラフ市場2023年：企業・地域・タイプ・用途別分析
  • 世界のアンモニアN-13市場2023年：企業・地域・タイプ・用途別分析

    • ◆H&Iグローバルリサーチのお客様（例）◆